HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany; Infektiologikum, Frankfurt am Main, Germany.
Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany.
JACC Cardiovasc Imaging. 2021 Aug;14(8):1548-1557. doi: 10.1016/j.jcmg.2021.01.042. Epub 2021 Apr 14.
The goal of this study was to examine prognostic relationships between cardiac imaging measures and cardiovascular outcome in people living with human immunodeficiency virus (HIV) (PLWH) on highly active antiretroviral therapy (HAART).
PLWH have a higher prevalence of cardiovascular disease and heart failure (HF) compared with the noninfected population. The pathophysiological drivers of myocardial dysfunction and worse cardiovascular outcome in HIV remain poorly understood.
This prospective observational longitudinal study included consecutive PLWH on long-term HAART undergoing cardiac magnetic resonance (CMR) examination for assessment of myocardial volumes and function, T1 and T2 mapping, perfusion, and scar. Time-to-event analysis was performed from the index CMR examination to the first single event per patient. The primary endpoint was an adjudicated adverse cardiovascular event (cardiovascular mortality, nonfatal acute coronary syndrome, an appropriate device discharge, or a documented HF hospitalization).
A total of 156 participants (62% male; age [median, interquartile range]: 50 years [42 to 57 years]) were included. During a median follow-up of 13 months (9 to 19 months), 24 events were observed (4 HF deaths, 1 sudden cardiac death, 2 nonfatal acute myocardial infarction, 1 appropriate device discharge, and 16 HF hospitalizations). Patients with events had higher native T1 (median [interquartile range]: 1,149 ms [1,115 to 1,163 ms] vs. 1,110 ms [1,075 to 1,138 ms]); native T2 (40 ms [38 to 41 ms] vs. 37 ms [36 to 39 ms]); left ventricular (LV) mass index (65 g/m [49 to 77 g/m] vs. 57 g/m [49 to 64 g/m]), and N-terminal pro-B-type natriuretic peptide (109 pg/l [25 to 337 pg/l] vs. 48 pg/l [23 to 82 pg/l]) (all p < 0.05). In multivariable analyses, native T1 was independently predictive of adverse events (chi-square test, 15.9; p < 0.001; native T1 [10 ms] hazard ratio [95% confidence interval]: 1.20 [1.08 to 1.33]; p = 0.001), followed by a model that also included LV mass (chi-square test, 17.1; p < 0.001). Traditional cardiovascular risk scores were not predictive of the adverse events.
Our findings reveal important prognostic associations of diffuse myocardial fibrosis and LV remodeling in PLWH. These results may support development of personalized approaches to screening and early intervention to reduce the burden of HF in PLWH (International T1 Multicenter Outcome Study; NCT03749343).
本研究旨在探讨接受高效抗逆转录病毒治疗(HAART)的人类免疫缺陷病毒(HIV)感染者(PLWH)心脏影像学指标与心血管结局之间的预后关系。
与未感染者相比,PLWH 患心血管疾病和心力衰竭(HF)的比例更高。HIV 导致心肌功能障碍和心血管预后恶化的病理生理驱动因素仍知之甚少。
这项前瞻性观察性纵向研究纳入了长期接受 HAART 治疗且正在接受心脏磁共振(CMR)检查以评估心肌容积和功能、T1 和 T2 映射、灌注和瘢痕的连续 PLWH。从索引 CMR 检查到每位患者的首次单一事件进行时间到事件分析。主要终点是经裁定的不良心血管事件(心血管死亡、非致死性急性冠脉综合征、适当的器械放电或有记录的 HF 住院)。
共纳入 156 名参与者(62%为男性;年龄[中位数,四分位间距]:50 岁[42 至 57 岁])。在中位随访 13 个月(9 至 19 个月)期间,观察到 24 例事件(4 例 HF 死亡、1 例猝死、2 例非致死性急性心肌梗死、1 例适当的器械放电和 16 例 HF 住院)。发生事件的患者具有更高的原生 T1(中位数[四分位间距]:1149 ms[1115 至 1163 ms]比 1110 ms[1075 至 1138 ms]);原生 T2(40 ms[38 至 41 ms]比 37 ms[36 至 39 ms]);左心室(LV)质量指数(65 g/m[49 至 77 g/m]比 57 g/m[49 至 64 g/m])和 N 末端 B 型利钠肽前体(109 pg/l[25 至 337 pg/l]比 48 pg/l[23 至 82 pg/l])(均 p<0.05)。多变量分析中,原生 T1 独立预测不良事件(卡方检验,15.9;p<0.001;原生 T1[10 ms]的危险比[95%置信区间]:1.20[1.08 至 1.33];p=0.001),其次是还包括 LV 质量的模型(卡方检验,17.1;p<0.001)。传统心血管风险评分不能预测不良事件。
我们的发现揭示了 PLWH 弥漫性心肌纤维化和 LV 重构的重要预后相关性。这些结果可能支持开发个性化的筛查和早期干预方法,以降低 PLWH 中 HF 的负担(国际 T1 多中心结局研究;NCT03749343)。